Private company
Lind Global Fund III LP
Private equity fund that raised $43.8 million in 2025 (SEC Form D). Summary from the record
Last updated Oct 21, 2026.
Overview
Corporate structure
Lind Global Fund III LP sits at the top of its group. 12 entities, 3 countries on record. Switch between the flow chart and the network, and select any entity to see its details.
- Lind Global Fund III LP DE
- 60 DEGREES PHARMACEUTICALS, INC. Stake · Washington, the District of Columbia
- BioNano Genomics Stake · San Diego, California, United States
- C3is Inc. Stake · 1T
- Dare Bioscience, Inc. Stake · San Diego, California
- DEFSEC Technologies Inc. Stake · A1
- Enveric Biosciences, Inc. Stake · Cambridge, Massachusetts
- FibroBiologics, Inc. Stake · Houston, Texas, United States
- Innovation Beverage Group Ltd Stake · C3
- Iveda Solutions, Inc. Stake · Mesa, Arizona
- Nuwellis, Inc. Stake · Eden Prairie, Minnesota, United States
- Silexion Therapeutics Corp Stake · George Town, Cayman Islands
Built from major holders from Schedules 13D and 13G; stakes of 5% or more it reported on Schedules 13D and 13G (11 companies). Each entity in the chart links to its source.
Leadership
Named in SEC Form D filings
People the company listed in its private-offering notices.
- Mr. Easton is the founder and Chief Investment Officer of the General Partner and the Investment Manager of the Issuer.Jeffrey L. Easton named Jun 6, 20252
Filings
1 filings to the SEC since October 2021: 1 private raises. The latest 1:
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Stakes it holds
Lind Global Fund III LP has told the SEC it owns more than 5% of 11 companies, latest first (Schedules 13D and 13G).
- Dare Bioscience, Inc.SCHEDULE 13G Aug 28, 20263
- DEFSEC Technologies Inc.SCHEDULE 13G Dec 23, 2025 to Aug 25, 20264
- Enveric Biosciences, Inc.SCHEDULE 13G/A Feb 4, 2026 to Aug 14, 20265
- Iveda Solutions, Inc.SCHEDULE 13G/A Feb 19, 2026 to Aug 14, 20266
- 60 DEGREES PHARMACEUTICALS, INC.SCHEDULE 13G Aug 5, 20267
- Nuwellis, Inc.SCHEDULE 13G Aug 5, 20268
- C3is Inc.SCHEDULE 13G Jul 31, 20269
- Innovation Beverage Group LtdSCHEDULE 13G/A Mar 20, 2026 to May 15, 202610
- Silexion Therapeutics CorpSCHEDULE 13G/A Sep 18, 2025 to May 15, 202611
- FibroBiologics, Inc.SCHEDULE 13G Apr 9, 202612
- BioNano GenomicsSCHEDULE 13G/A Sep 24, 2025 to Feb 17, 202613
Funding
Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.
- Private raises (Form D) $43.8M
Figures by year
| Year | Private raises (Form D) | Total |
|---|---|---|
| 2025 | $43.8M | $43.8M |
Private raises
Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13